Tepezza

News

Broken image of a woman through eyes in double-vision

FDA clears Roche's Enspryng for thyroid eye disease

Roche has claimed US approval for Enspryng in a second indication, thyroid eye disease, that makes it a rival to drugs from Amgen and Viridian.

News

FDA clears Viridian's Tepezza rival for thyroid eye disease

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Dyvyzat box, bottle, and oral delivery mechanism.

Italfarmaco closes on EU okay for Duchenne drug

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

Sling shoots at thyroid eye disease with its oral therapy

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

FDA clears Roche's Enspryng for thyroid eye disease

FDA clears Viridian's Tepezza rival for thyroid eye disease

Amgen scores with new thyroid eye disease formulation

Italfarmaco closes on EU okay for Duchenne drug

Sling shoots at thyroid eye disease with its oral therapy

Viridian takes aim at Amgen's Tepezza with veligrotug data

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Tepezza

Editor's Picks